Skip to main content
Top
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Statins | Research

Association of statin use and increase in lipoprotein(a): a real-world database research

Authors: Tienan Feng, Yao Li, Xiongfeng Xue, Wei Yang, Qiang Li, Yushi Huang, Tengteng Zhu, Jue Wang, Limin Xu, Xianchen Li, Jing Gao, Shiming Sun, Bin Zhu, ShuYu Zhang, Beibei Cao, Jianwei Xuan, Zhigang Zhao, Biyun Qian

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

There is an increased concern that statins may have an unintended effect of elevated lipoprotein(a) [Lp(a)]. We conducted a large sample real-world study to test the association.

Methods

This retrospective cohort study was conducted using data from an integrated SuValue database, which includes 221 hospitals across China covering more than 200,000 of population with longitudinal follow-up to 10 years. Propensity score matching was applied to identify two comparable cohorts with statin users and non-statin users. Detailed follow-up information such as Lp(a) levels were extracted. The hazard ratio was calculated on Lp(a) changes based on the statin usage cohorts. Detailed subgroup and different characteristic cohorts’ analyses were also conducted.

Results

After baseline propensity score matching, a total of 42,166 patients were included in a 1:1 matched ratio between statin users and non-statin users. In the case of no difference in low density lipoprotein (LDL-C), Lp(a) was increased significantly with the use of statins (adjusted HR 1.47; 95% confidence interval [CI] 1.43–1.50). Lp(a) increase was observed in various subgroup analyses and different cohorts. The dose intensity of statin was positively associated with the evaluated Lp(a) level.

Conclusion

The use of statins was associated with an increased risk of Lp(a) elevation compared with non-statin use counterparts. The clinical relevance of these increases needs to be addressed in surrogate marker trials and/or large, cardiovascular outcomes trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference BlascoI PG, LevitesII MR, de PaulaII PS, United States Preventive Services Task Force (USPSTF). recomendações atualizadas para o rastreamento do câncer colorretal. Diagn tratamento. 2016;2017:28–9. BlascoI PG, LevitesII MR, de PaulaII PS, United States Preventive Services Task Force (USPSTF). recomendações atualizadas para o rastreamento do câncer colorretal. Diagn tratamento. 2016;2017:28–9.
2.
go back to reference Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80(5):1313–9.CrossRefPubMed Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80(5):1313–9.CrossRefPubMed
3.
go back to reference Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615–22.CrossRefPubMed Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615–22.CrossRefPubMed
4.
go back to reference Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390–9.CrossRefPubMed Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390–9.CrossRefPubMed
5.
go back to reference Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011;183(16):E1189–202.CrossRefPubMedPubMedCentral Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011;183(16):E1189–202.CrossRefPubMedPubMedCentral
6.
go back to reference Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153(12):800–8.CrossRefPubMed Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153(12):800–8.CrossRefPubMed
7.
go back to reference Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis. 2016;245:161–70.CrossRefPubMed Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis. 2016;245:161–70.CrossRefPubMed
8.
go back to reference Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein (a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. The Lancet. 2018;392(10155):1311–20.CrossRef Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein (a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. The Lancet. 2018;392(10155):1311–20.CrossRef
9.
go back to reference Tsimikas S, Gordts PL, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein (a) levels. European Heart J. 2020;41(24):2275–84. CrossRef Tsimikas S, Gordts PL, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein (a) levels. European Heart J. 2020;41(24):2275–84. CrossRef
10.
go back to reference Kronenberg F. Therapeutic lowering of lipoprotein (a): How much is enough? Atherosclerosis. 2019;288:163–5.CrossRefPubMed Kronenberg F. Therapeutic lowering of lipoprotein (a): How much is enough? Atherosclerosis. 2019;288:163–5.CrossRefPubMed
11.
go back to reference Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91(5):1403–9.CrossRefPubMed Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91(5):1403–9.CrossRefPubMed
12.
go back to reference de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(5):779–92.CrossRefPubMed de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(5):779–92.CrossRefPubMed
13.
go back to reference Wang X, Li J, Ju J, Fan Y, Xu H. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: a network meta-analysis. Pharmacol Res. 2021;163: 105275.CrossRefPubMed Wang X, Li J, Ju J, Fan Y, Xu H. Effect of different types and dosages of statins on plasma lipoprotein(a) levels: a network meta-analysis. Pharmacol Res. 2021;163: 105275.CrossRefPubMed
15.
go back to reference Cannas M, Arpino B. Matching with clustered data: the CMatching package in R. The R Journal. 2019;11(1):7–21.CrossRef Cannas M, Arpino B. Matching with clustered data: the CMatching package in R. The R Journal. 2019;11(1):7–21.CrossRef
16.
go back to reference Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311–20.CrossRefPubMed Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311–20.CrossRefPubMed
17.
go back to reference Chamberlain AM, Cohen SS, Weston SA, Fox KM, Xiang P, Killian JM, et al. Relation of cardiovascular events and deaths to low-density lipoprotein cholesterol level among statin-treated patients with atherosclerotic cardiovascular disease. Am J Cardiol. 2019;123(11):1739–44.CrossRefPubMedPubMedCentral Chamberlain AM, Cohen SS, Weston SA, Fox KM, Xiang P, Killian JM, et al. Relation of cardiovascular events and deaths to low-density lipoprotein cholesterol level among statin-treated patients with atherosclerotic cardiovascular disease. Am J Cardiol. 2019;123(11):1739–44.CrossRefPubMedPubMedCentral
18.
go back to reference Alagona P. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009;15(3 Suppl):S65-73.PubMed Alagona P. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009;15(3 Suppl):S65-73.PubMed
19.
go back to reference Shingo Minatoguchi KY, Vengrenyuk Y, Sweeny J, Krishnamoorthy P, Suleman J, Moreno P, Narula J, Sharma S, Kini A. TCT-577 Lipoprotein(a) and intracoronary imaging after intensive statin treatment. J Am College Cardiol. 2022;80(12):B238.CrossRef Shingo Minatoguchi KY, Vengrenyuk Y, Sweeny J, Krishnamoorthy P, Suleman J, Moreno P, Narula J, Sharma S, Kini A. TCT-577 Lipoprotein(a) and intracoronary imaging after intensive statin treatment. J Am College Cardiol. 2022;80(12):B238.CrossRef
20.
go back to reference Kouvari M, Panagiotakos DB. The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention: a systematic review of epidemiological studies. Curr Opin Cardiol. 2019;34(4):424–34.CrossRefPubMed Kouvari M, Panagiotakos DB. The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention: a systematic review of epidemiological studies. Curr Opin Cardiol. 2019;34(4):424–34.CrossRefPubMed
21.
go back to reference Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler Thromb Vasc Biol. 2020;40(1):255–66.CrossRefPubMed Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arterioscler Thromb Vasc Biol. 2020;40(1):255–66.CrossRefPubMed
22.
go back to reference Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764.CrossRefPubMedPubMedCentral Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764.CrossRefPubMedPubMedCentral
23.
go back to reference Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–28.CrossRefPubMed Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–28.CrossRefPubMed
24.
go back to reference Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statins and increases in Lp(a): an inconvenient truth that needs attention. Eur Heart J. 2019;41(1):192–3.CrossRef Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statins and increases in Lp(a): an inconvenient truth that needs attention. Eur Heart J. 2019;41(1):192–3.CrossRef
25.
go back to reference Pirillo A, Catapano AL. Statins increase Lp(a) plasma level: is this clinically relevant? Eur Heart J. 2020;41(24):2285–87.CrossRef Pirillo A, Catapano AL. Statins increase Lp(a) plasma level: is this clinically relevant? Eur Heart J. 2020;41(24):2285–87.CrossRef
26.
go back to reference Emdin CA, Khera AV, Natarajan P, Klarin D, Won H-H, Peloso GM, et al. Phenotypic characterization of genetically lowered human lipoprotein (a) levels. J Am Coll Cardiol. 2016;68(25):2761–72.CrossRefPubMedPubMedCentral Emdin CA, Khera AV, Natarajan P, Klarin D, Won H-H, Peloso GM, et al. Phenotypic characterization of genetically lowered human lipoprotein (a) levels. J Am Coll Cardiol. 2016;68(25):2761–72.CrossRefPubMedPubMedCentral
27.
go back to reference Group L-TIwPiIDS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–57.CrossRef Group L-TIwPiIDS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–57.CrossRef
28.
go back to reference Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001–9.CrossRefPubMed Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001–9.CrossRefPubMed
29.
go back to reference Group SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344(8934):1383–9. Group SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344(8934):1383–9.
30.
go back to reference Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.CrossRefPubMedPubMedCentral Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.CrossRefPubMedPubMedCentral
Metadata
Title
Association of statin use and increase in lipoprotein(a): a real-world database research
Authors
Tienan Feng
Yao Li
Xiongfeng Xue
Wei Yang
Qiang Li
Yushi Huang
Tengteng Zhu
Jue Wang
Limin Xu
Xianchen Li
Jing Gao
Shiming Sun
Bin Zhu
ShuYu Zhang
Beibei Cao
Jianwei Xuan
Zhigang Zhao
Biyun Qian
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Statins
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01155-x

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue